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Abstract
A thoracic aortic aneurysm (TAA) is a potentially life-threatening condition with
structural weakness of the aortic wall, which can progress to arterial dilatation
and rupture. Today, both an increasing awareness of vascular disease and the
access to tomographic imaging facilitate the diagnosis of TAA even in an
asymptomatic stage. The risk of rupture for untreated aneurysms beyond
a diameter of 5.6 cm ranges from 46% to 74% and the two-year mortality rate is
greater than 70%, with most deaths resulting from rupture. Treatment options
include surgical and non-surgical repair to prevent aneurysm enlargement and
rupture. While most cases of ascending aortic involvement are subject to surgical
repair (partially with valve-preserving techniques), aneurysm of the distal arch
and descending thoracic aorta are amenable to emerging endovascular techniques
as an alternative to classic open repair or to a hybrid approach (combining
debranching surgery with stent grafting) in an attempt to improve outcomes. 
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Introduction
Over the past 30 years, the reported incidence of thoracic aortic
aneurysm (TAA) has increased with better diagnostics and with more
patients living to advanced age. Little is known, however, about the true
prevalence and mortality rate of TAA in a particular population [1, 2].
A population-based study in Rochester, Minnesota reported an age- and
gender-adjusted incidence of 5.9 new aneurysms per 100 000 person-
years in a Midwestern community over a 30-year period with median
ages of 65 years for men and 77 years for women and a distribution of
aortic segments as follows: the ascending aorta was involved in 51%,
the arch in 11%, and the descending thoracic aorta in 38% [3, 4]. The
pathogenesis of aortic aneurysms has not been established fully, but it
is believed to be multifactorial and include atherosclerosis, increased
tissue protease activity, antiprotease deficiency, mechanical factors,
inflammatory disorders, infection and genetic collagen defects such as
Marfan syndrome and type IV Ehlers-Danlos syndrome. Up to 20% of
patients with an aneurysm have a first-degree relative with the same
disorder, which suggests a genetic link [5]. The aetiology of TAA is most
often aortic dissection in 53%, arteriosclerosis in 29%, aortitis in 8%,
cystic medial necrosis in 6%, and syphilis in 4% [6]. The natural history
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of thoracic aortic aneurysms has not been
sufficiently defined. One reason for this is that
both the aetiology and location of an aneurysm
may affect its rate of growth and propensity for
dissection or rupture. The Yale group showed in
their longitudinal data that the mean rate of
growth for all thoracic aneurysms was significantly
lower (0.1 cm/y) than that of abdominal
aneurysms (0.2-0.5 cm/y) [2]. The rate of growth,
however, was greater for aneurysms of the
descending aorta versus the ascending aorta, was
greater for dissected versus non-dissected
aneurysms, and was most pronounced in Marfan
syndrome [2]. Initial size can also be an important
predictor of the rate of thoracic aneurysm growth;
a study based on 721 patients supported the fact
that TAA size had a profound impact on risk for
rupture, with an annual rate of 2% in aneurysms
< 5 cm, 3% in aneurysms 5-5.9 cm, and 7% for
aneurysms over 6 cm in diameter. Therefore the
risk appears to rise abruptly as thoracic aneurysms
reach a size of 6 cm [7, 8]. In several series
aneurysm rupture occurred in 32% to 68% of
medically treated patients and rupture accounted
for 32% to 47% of deaths; thus the 1-, 3- and 5-year
survival rate of thoracic aneurysms left without
repair was 65%, 36% and 20%, respectively [9, 10].
While most cases of ascending aortic involvement
are subject to surgical repair (partially with valve-
preserving techniques), aneurysms of the distal
arch and descending thoracic aorta are amenable
to emerging endovascular techniques as an
alternative to classic open repair or to a hybrid
approach (combining debranching surgery with
stent grafting) in an attempt to improve outcomes.
Endovascular repair
Endovascular treatment of thoracic aortic
aneurysms is achieved by transluminal placement
of one or more stent-graft devices across the
longitudinal extent of the lesion. The prosthesis
bridges the aneurismal sac to exclude it from 
high-pressure aortic blood flow, thereby allowing
for sac thrombosis around the stent graft and
possible remodelling of the aortic wall (Figure 1).
Thoracotomy, aortic cross-clamping, left-heart
bypass, and single-lung ventilation are all avoided
with an endovascular aortic procedure. The use 
of stent grafts was first reported by Volodos 
et al. in 1986 in a patient with post-traumatic
pseudoaneurysm of the thoracic aorta [11]. With
technology proceeding at a fast pace, both custom-
designed and commercially available stent grafts
are available for treating thoracic aortic disease
(Figure 2). By now, several institutions have
substantiated both the safety and the effectiveness
of stent grafts for the repair of thoracic aortic
aneurysms [12-14]. With increasing endovascular
experience numerous other aortic diseases, such
as aortic dissection, penetrating atherosclerotic
ulcers, aortopulmonary fistulas, acute aortic rupture
from blunt chest trauma, and mycotic aneurysms,
have been investigated as a potential indication for
endovascular treatment.  
Technique
Currently, there is ongoing controversy over
which patients should be treated by endovascular
means (Table I). The long-term durability of aortic
stent grafts is not yet known, and therefore
Figure 1. (A) CT angiogram showing a circumscript aneurysm of the descending thoracic aorta in a middle-aged male
patient selected for endografting. (B) 1-year follow-up after successful endovascular exclusion of the aneurysm by
stent-graft placement demonstrates marked shrinkage of periprosthetic aneurysm and optimal wall apposition of
the stent graft
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cautious patient selection is advocated. The
suitability of a given patient for endovascular repair
is based on both clinical and anatomical
considerations. At present, stent grafts are routinely
used to treat patients with thoracic aneurysms
distal to the aortic arch. Inoue et al. have performed
aortic arch reconstructions using transluminally
placed endovascular branched stent grafts to treat
aneurysms involving the aortic arch. This concept,
however, was a failure, with many complications,
and was not embraced in the community.
Successful TAA exclusion requires normal segments
of native aorta at both ends of the lesion of at least
15 mm to 25 mm to ensure adequate launching and
contact between the stent graft and the aortic wall
with a tight circumferential seal. Devices are
oversized by 10% in diameter to provide sufficient
radial force for adequate fixation [15]. The preferred
and most common site (41-58%) of vascular access
is the common femoral artery [16, 17]. Less
frequently, access to the iliac artery (9-44%) 
via an extra-peritoneal approach is required.
Retroperitoneal exposure to the abdominal aorta
is necessary in 14-30% of cases, especially in small,
elderly women [16, 17]. In patients with multiple
aortic aneurysms involving both the thoracic and
abdominal aorta a combination of conventional
abdominal aortic replacement with endovascular
stent-graft placement into the thoracic aorta under
fluoroscopic guidance is feasible [18]. Care must be
taken not to occlude major arterial branches or to
bypass them prior to stent-graft placement.
A rational approach to endovascular treatment of
aortic aneurysms with a short proximal neck is
transposition of the left subclavian artery prior to
stent-graft placement. After deployment short
inflation of a latex balloon should be performed to
improve apposition of the stent struts to the aortic
wall. Post-procedurally, both Doppler-ultrasound
and contrast fluoroscopy should be performed to
document the immediate result. After removing the
sheath and guide wire the access sites can be
closed in standard surgical fashion.
Hybrid procedures for aortic arch pathologies
The aortic arch morphology is challenging
because of angulations and the proximity of 
the supra-aortic branches, which need to be
preserved. Traditional open arch reconstruction
using hypothermic cardiac arrest, extracorporeal
circulation and selective cerebral perfusion has been
demonstrated to effectively manage aortic arch
pathologies. However, this current standard
procedure for any arch pathology carries significant
mortality (2-9%) and risk of paraplegia and cerebral
stroke in 4-13% of cases [19]. Therefore, open repair
is often reserved for low-risk patients. Hybrid arch
procedures (HAP) are a combination of debranching
AB C
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Figure 2. A selection of thoracic stent grafts currently available for endoluminal repair. Zenith TX2 by Cook Medical
(A), TAG by GORE (B); Valiant by Medtronic AVE (C); Relay Thoracic Stent-Graft by Bolton Medical (D); EndoFit by
LeMaitre Vascular (E)
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bypass (supra-aortic vessel transposition) to
establish cerebral perfusion and subsequent
thoracic endografting to provide patient-centred
solutions for complex aortic arch lesions (Figure 3).
HAP is performed without hypothermic circulatory
arrest and extracorporeal circulation and could
expand the treatment group to older patients with
severe comorbidities and redo-surgery currently
ineligible for open surgical intervention. There are
two different hybrid approaches with either extra-
anatomic or intrathoracic supra-aortic vessel
transposition. To treat distal arch aneurysms
involving both the left subclavian and the left
common carotid artery, those vessels can be
translocated upstream to the right common carotid
artery approached via cervical access (hemi-arch
debranching) [20]. For arch aneurysms extending
to the innominate artery the ascending aorta can
be used, via sternotomy, as a donor site to
revascularize all three supra-aortic arteries (total
arch debranching). The key to success is the quality
of the unimpaired ascending aorta as a donor site
for the debranching bypass and proximal landing
zone for the stent grafts. 
Follow-up
When a thoracic aortic aneurysm is first detected
its growth rate is not known yet. It is therefore
appropriate to obtain a repeated imaging study 
6 months after the initial study. If the aneurysm is
unchanged in size, it is then reasonable to obtain
an imaging study on an annual basis in most cases.
In non-Marfan patients and in the absence of acute
aortitis, thoracic aortic aneurysms tend to grow
slowly and annual imaging is sufficient for
surveillance. However, should there be a significant
increase in aortic size per year (> 0.5 cm per year),
action is required or at least shorter imaging follow-
up. Follow-up examinations should be performed
at discharge, 6 and 12 months and annually
thereafter. Imaging studies include helical CT and
3D reconstruction, or if endotension is suspected,
MR angiography is the preferred method of
evaluation. 
Results from the literature
Primary technical success was generally defined
as complete exclusion of the TAA, stent-graft
patency, and restoration of normal blood flow
immediately after endovascular repair (EVR).
Secondary technical success was defined as
complete TAA exclusion, graft patency, and
restoration of blood flow within 30 days of stent-
graft placement. Several studies have reported high
success rates with 85% to 100% of procedures in
successful deployment and functional exclusion of
the aneurysm. Major complications occurred in 
14-18% of patients depending on the acuity at
presentation, with very low incidence of paraplegia.
In the recent literature, different groups had
periprocedural stroke rates of 0% to 7% [17, 21] and
incidence rates for paraplegia between 0% and 5%
[17, 21-23]. Although low, these rates remain
significant, especially because it is impossible to re-
implant intercostal arteries in this setting. Endoleak
is the Achilles heel of endovascular stent-graft
procedures. The rate of endoleak immediately after
TAA stent-graft placement has been reported to be
between 4% and 24% [23, 24].
Early and late mortality rate ranged from 0 to
14% and is usually attributable to the preoperative
status of the patients. Most studies showed
Disease aetiology
Aortic aneurysms
Atherosclerotic/degenerative
Post-traumatic
Mycotic
Anastomotic
Cystic medial necrosis
Aortitis
Stanford type B aortic dissection
Acute
Chronic
Giant penetrating ulcer
Traumatic aortic tear
Aortopulmonary fistula
Marfan syndrome
Aneurysm morphology
Aneurysm of the descending aorta
Proximal neck length = 2 cm
< 2 cm if supra-aortic vessels have been transposed 
prior to stent-graft placement
Distal neck length = 2 cm
Diameter > 6 cm
Patient condition
Preferentially older age
Unfit for open surgical repair or high-risk patients
Chronic obstructive pulmonary disease
Severe coronary heart disease
Severe carotid artery disease
Renal insufficiency
Suitable vascular access site
Life expectancy of more than 6 months
Table I. Current indications for endovascular treat  -
ment of thoracic aortic disease
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Figure 3. Contrast-medium enhanced MR angiography of the aorta in a case of aortic arch aneurysm. A – aneurysm
of the aortic arch involving the supra-aortic branches. B – post-interventional/-surgical result after hybrid procedure
with debranching of the supra-aortic vessels and stent-graft implantation in the aortic arch
A B
Author, year N Follow-up Technical  30-day Paraplegia Endoleak Long-term  Devices
[month] success [%] mortality [%] [%] [%] survival [%]
Dake, 1998 [17] 103 22 83 9 3 24 73 (2 years) Homemade
Ehrlich, 1998 [23] 10 NA 80 10 0 20 NA Talent
Cartes-Zumelzu, 32 16 90.6 9.4 3.1 15.4 90.2  Excluder, 
2000 [24] (32 months) Talent
Grabenwoger, 21 NA 100 9.5 0 14.3 NA Talent, 
2000 [30] Prograft
Najibi, 2002 [31] 24 12 94.7 5.3 0 0 89.5 (1 year)  Excluder, Talent
Heijmen, 2002 [32] 28 21 96.4 0 0 28.6 96.4  Talent, 
(21 months) Excluder
Schoder, 2003 [33] 28 22.7 100 0 0 25 80.2 (3 years) Excluder
Bell, 2003 [34] 67 17 NA 2 4 4.8 89 (1 year) Gore, Talent
Lepore, 2003 [35] 21 12 100 9.5 4.8 19 76.2 (1 year) Excluder, Talent
Ouriel, 2003 [36] 31 6 NA 12.9 6.5 32.3 81.6 (6 months) Excluder, Talent
Czerny, 2004 [37] 54 38 94.4 9.3 0 27.8 63 (3 years) Excluder, Talent
Makaroun, 2004 [38] 142 29.6 97.9 1.5 3.5 8.8 75 (2 years) TAG
Leurs, 2004 [39] 249 32 87 10.4 4 4.2 80.1 (1 year) Excluder, Talent,
Zenith, Endofit
Glade, 2005 [40] 42 15 NA NA 2 NA NA Gore, Talent
Greenberg, 2005 [41] 100 14 NA NA 1 6 83 (1 year) Zenith
Riesenmann, 2005 [42] 50 9 96 NA 0 10 79.4 (1 year) Talent
Ricco, 2006 [43] 166 NA NA 5 3.6 16.2 NA Gore, Talent
Wheatley, 2006 [44] 156 21.5 98.7 3.8 0.6 11.5 76.6 (1 year) Gore
Bavaria, 2007 [45] 140 24 98 2.1 2.9 10 NA Gore
Qu, 2008 [46] 46 15.2 100 9.2 3.4 5.8 88.5 (2 years) EndoFit
Ting, 2009 [47] 24 21 98 NA 0 NA 75 (2 years) AneuRx, Talent, 
Zenith, Excluder
Table II. Overview of published data regarding endovascular treatment of thoracic aortic aneurysm
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a patient survival rate of 70-80% at 1, 3 and 5 years.
(Table II) [17, 21-47]. Data from 457 patients treated
with stent grafts and collected in a registry 
(113 emergency and 344 elective cases) revealed
that among 422 patients who survived the
interventional procedure (in-hospital mortality 5%),
mortality during follow-up was 8.5% (36 patients),
of which 11 patients had died from the aortic
disease; persistent endoleak was reported in
64 cases, of which 44 were primary (9.6%) and 
21 occurred during follow-up (4.9%) [25]. Kaplan-
Meier overall survival estimate at 1, 3 and 5 years
was 90.9%, 85.4% and 77.5%. At the same intervals,
freedom from a second procedure (either open
conversion or endovascular) was 92.5%, 81.3%, and
70.0%, respectively [25]. At Stanford University first-
generation thoracic aortic grafting was performed
in 103 patients from 1992 to 1997. Of these
patients, 60% were deemed unsuitable for open
standard aortic replacement [26]. The average
diameter of the aneurysms was 6 cm (range 
4-11 cm), and the length varied from 1 cm in post-
traumatic aneurysm to 22 cm. In 8 patients
a preoperative subclavian-to-carotid bypass or
transposition was performed to allow the orifice of
the subclavian artery to be covered with the stent
graft without obstructing flow to the arm. The
mortality rate in this pioneering study was 9%, with
a 3% incidence of paraplegia. Complete exclusion
of the aneurysm occurred in 84% of patients and
endoleaks were observed in 25 patients (24%);
these were subsequently successfully treated in 
11 patients by a combination of overstenting and
coiling. The survival rate was 81% at 1 year and 73%
at 2 years. Late rupture occurred in 2% of patients
at 22-month average follow-up [26]. A 6-year
prospective case series involving 84 patients was
completed by Ellozy et al. [29]. Primary technical
success was achieved in 90%, and successful
exclusion of the aneurysm was achieved in 82%.
However, major procedure-related or device-related
complications occurred in 38%, including proximal
attachment failure (8%), distal attachment failure
(6%), mechanical device failure (3%), periprocedural
death (6%), and late aneurysm rupture (6%). More
encouraging was the fact that only 3% suffered
persistent neurological complications [29]. 
For aneurysm disease encompassing the
descending thoracic aorta and in selected cases the
distal aortic arch, use of endovascular stent grafts for
repair of suitable anatomical conditions is a promising,
non-surgical alternative; however, morphology and
graft sizing are paramount in case selection. 
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